GGrantIndex
← Leaderboards

Jun O. Liu

Johns Hopkins University

$22,989,575
Attributed
$25,774,220
Total exposure
16
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$25,774,220 · 16

By mechanism

R01$13,627,985 · 7
DP1$4,042,846 · 2
T32$3,144,228 · 1
RC4$2,524,394 · 1
RF1$1,830,581 · 1
R21$372,851 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Proteins

Research focus

ProteinsIn VivoCellsAnalogMolecularPlayLibrariesPharmaceutical PreparationsAntineoplastic AgentsLeadAngiogenesis InhibitorsMediatingStructureAngiogenesisComplexProtein IsoformsNamesAnimal ModelCombinatorialSpecificityCell ProliferationInvestigationEndothelial CellsInhibitor/Antagonist

Grant awards (66)

Characterization of A Novel Proteasome Inhibitor$517,344
R01 · FY2025 · GM · contact PI
Rapireon, a new macrocycle molecular glue that selectively activates the nuclease activity of IRE1$1,830,581
RF1 · FY2024 · NS · contact PI
Characterization of A Novel Proteasome Inhibitor$519,833
R01 · FY2024 · GM · contact PI
Characterization of A Novel Proteasome Inhibitor$521,599
R01 · FY2023 · GM · contact PI
Targeting Glucose Transporters Using Rapafucins$335,688
R01 · FY2023 · GM · contact PI
Characterization of A Novel Proteasome Inhibitor$491,813
R01 · FY2022 · GM · contact PI
Targeting Glucose Transporters Using Rapafucins$335,688
R01 · FY2022 · GM · contact PI
Targeting Glucose Transporters Using Rapafucins$335,688
R01 · FY2021 · GM · contact PI
Targeting Glucose Transporters Using Rapafucins$335,688
R01 · FY2020 · GM · contact PI
Studies of the Antifungal Drug Itraconazole As A Novel Inhibitor of Angiogenesis$359,457
R01 · FY2019 · CA · contact PI
Studies of the Antifungal Drug Itraconazole As A Novel Inhibitor of Angiogenesis$370,575
R01 · FY2018 · CA · contact PI
Studies of the Antifungal Drug Itraconazole As A Novel Inhibitor of Angiogenesis$370,575
R01 · FY2017 · CA · contact PI
Chemical biology of superstolides--a novel class of anticancer natural products$166,555
R21 · FY2017 · CA
Studies of the Antifungal Drug Itraconazole As A Novel Inhibitor of Angiogenesis$370,575
R01 · FY2016 · CA · contact PI
Chemical biology of superstolides--a novel class of anticancer natural products$206,296
R21 · FY2016 · CA
Studies of the Antifungal Drug Itraconazole As A Novel Inhibitor of Angiogenesis$370,575
R01 · FY2015 · CA · contact PI
Pharmacology Training Grant$319,295
T32 · FY2015 · GM · contact PI
Generation and Proteome-Wide Screening of Hybrid Combinatorial Libraries$811,800
DP1 · FY2014 · CA · contact PI
Pharmacology Training Grant$306,491
T32 · FY2014 · GM · contact PI
Generation and Proteome-Wide Screening of Hybrid Combinatorial Libraries$787,446
DP1 · FY2013 · CA · contact PI
Pharmacology Training Grant$312,582
T32 · FY2013 · GM · contact PI
Generation and Proteome-Wide Screening of Hybrid Combinatorial Libraries$811,800
DP1 · FY2012 · CA · contact PI
Structure, Function and Inhibition of Human Methionine Aminopeptidases$365,100
R01 · FY2012 · CA · contact PI
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs$330,091
R01 · FY2012 · CA · contact PI
Pharmacology Training Grant$312,582
T32 · FY2012 · GM · contact PI
Generation and Proteome-Wide Screening of Hybrid Combinatorial Libraries$811,800
DP1 · FY2011 · OD · contact PI
Structure, Function and Inhibition of Human Methionine Aminopeptidases$365,100
R01 · FY2011 · CA · contact PI
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs$330,091
R01 · FY2011 · CA · contact PI
Pharmacology Training Grant$309,316
T32 · FY2011 · GM · contact PI
High-Throughput Screen For FDA Approved Drugs That Amplify Beta-Cell Mass In Vivo$2,524,394
RC4 · FY2010 · DK
Generation and Proteome-Wide Screening of Hybrid Combinatorial Libraries$820,000
DP1 · FY2010 · OD · contact PI
Structure, Function and Inhibition of Human Methionine Aminopeptidases$376,391
R01 · FY2010 · CA · contact PI
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs$340,300
R01 · FY2010 · CA · contact PI
Pharmacology Training Grant$306,141
T32 · FY2010 · GM · contact PI
Structure, Function and Inhibition of Human Methionine Aminopeptidases$376,391
R01 · FY2009 · CA · contact PI
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs$340,300
R01 · FY2009 · CA · contact PI
Pharmacology Training Grant$302,713
T32 · FY2009 · GM · contact PI
Structure, Function and Inhibition of Human Methionine Aminopeptidases$376,391
R01 · FY2008 · CA · contact PI
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs$340,300
R01 · FY2008 · CA · contact PI
Pharmacology Training Grant$325,036
T32 · FY2008 · GM · contact PI
Inhibition of Angiogenesis by TNP 470 and Ovalicin$364,314
R01 · FY2007 · CA · contact PI
Pharmacology Training Grant$325,036
T32 · FY2007 · GM · contact PI
NF-kappaB Signaling Pathway Probed with Natural Products$310,442
R01 · FY2007 · CA · contact PI
Inhibition of Angiogenesis by TNP 470 and Ovalicin$375,196
R01 · FY2006 · CA · contact PI
Pharmacology Training Grant$325,036
T32 · FY2006 · GM · contact PI
NF-kappaB Signaling Pathway Probed with Natural Products$319,714
R01 · FY2006 · CA · contact PI
Inhibition of Angiogenesis by TNP 470 and Ovalicin$384,225
R01 · FY2005 · CA
NF-kappaB Signaling Pathway Probed with Natural Products$327,409
R01 · FY2005 · CA
Inhibition of Angiogenesis by TNP 470 and Ovalicin$384,225
R01 · FY2004 · CA
NF-kappaB Signaling Pathway Probed with Natural Products$327,409
R01 · FY2004 · CA
THE ROLE OF CAVEOLAE AND CAVEOLIN-1 IN ENDOTHELIAL CELL MIGRATION$172,829
P20 · FY2004 · RR
Inhibition of Angiogenesis by TNP 470 and Ovalicin$360,349
R01 · FY2003 · CA
NF-kappaB Signaling Pathway Probed with Natural Products$327,409
R01 · FY2003 · CA
SIGNAL TRANSDUCTION BY CALCINEURIN IN T LYMPHOCYTES$58,860
R01 · FY2003 · GM
INHIBITION OF ANGIOGENESIS BY TNP 470 AND OVALICIN$344,074
R01 · FY2002 · CA
CORE--SHARED EQUIPMENT RESOURCE$0
P30 · FY2002 · CA
INHIBITION OF ANGIOGENESIS BY TNP 470 AND OVALICIN$292,182
R01 · FY2001 · CA
SIGNAL TRANSDUCTION BY CALCINEURIN IN T LYMPHOCYTES$145,209
R01 · FY2001 · GM
MECHANISM(S) OF INHIBITION OF ANGIOGENESIS BY FUMAGILLIN, OVALICIN &TNP 470$53,566
P41 · FY2001 · RR
INHIBITION OF ANGIOGENESIS BY TNP 470 AND OVALICIN$42,518
R01 · FY2001 · CA
SIGNAL TRANSDUCTION BY CALCINEURIN IN T LYMPHOCYTES$3,442
R01 · FY2001 · GM
CORE--SHARED EQUIPMENT RESOURCE$0
P30 · FY2001 · CA
INHIBITION OF ANGIOGENESIS BY TNP 470 AND OVALICIN$325,601
R01 · FY2000 · CA
SIGNAL TRANSDUCTION BY CALCINEURIN IN T LYMPHOCYTES$159,854
R01 · FY2000 · GM
MECHANISM(S) OF INHIBITION OF ANGIOGENESIS BY FUMAGILLIN, OVALICIN &TNP 470$4,940
P41 · FY2000 · RR
CORE--SHARED EQUIPMENT RESOURCE$0
P30 · FY2000 · CA